Cargando…

Optimal Planning Target Volume Margins for Elective Pelvic Lymphatic Radiotherapy in High-Risk Prostate Cancer Patients

Purpose. High-risk prostate cancer patients often receive radiotherapy (RT) to pelvic lymphatics (PLs). The aim of this study was to determine the safety margin around clinical target volume for PL (PL-CTV) to construct planning target volume for PL (PL-PTV) and for planning elective PL irradiation....

Descripción completa

Detalles Bibliográficos
Autores principales: Hinton, Benjamin K., Fiveash, John B., Wu, Xingen, Dobelbower, Michael C., Kim, Robert Y., Jacob, Rojymon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606762/
https://www.ncbi.nlm.nih.gov/pubmed/23533814
http://dx.doi.org/10.1155/2013/941269
_version_ 1782264050058526720
author Hinton, Benjamin K.
Fiveash, John B.
Wu, Xingen
Dobelbower, Michael C.
Kim, Robert Y.
Jacob, Rojymon
author_facet Hinton, Benjamin K.
Fiveash, John B.
Wu, Xingen
Dobelbower, Michael C.
Kim, Robert Y.
Jacob, Rojymon
author_sort Hinton, Benjamin K.
collection PubMed
description Purpose. High-risk prostate cancer patients often receive radiotherapy (RT) to pelvic lymphatics (PLs). The aim of this study was to determine the safety margin around clinical target volume for PL (PL-CTV) to construct planning target volume for PL (PL-PTV) and for planning elective PL irradiation. Methods and Materials. Six patients who received RT to PL as part of prostate cancer treatment were identified. To determine average daily shifts of PL, the right and left IVs were contoured at 3 predetermined slices on the daily MV scans and their daily shifts were measured at these 3 levels using a measuring tool. Results. A total of 1,932 observations were made. Daily shifts of IV were random in distribution, and the largest observed shift was 13.6 mm in lateral and 15.4 mm in AP directions. The mean lateral and AP shifts of IV were 2.1 mm (±2.2) and 3.5 mm (±2.7), respectively. The data suggest that AP and lateral margins of 8.9 mm and 6.5 mm are necessary. Conclusions. With daily alignment to the prostate, we recommend an additional PL-CTV to PL-PTV conversion margin of 9 mm (AP) and 7 mm (lateral) to account for daily displacement of PL relative to the prostate.
format Online
Article
Text
id pubmed-3606762
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36067622013-03-26 Optimal Planning Target Volume Margins for Elective Pelvic Lymphatic Radiotherapy in High-Risk Prostate Cancer Patients Hinton, Benjamin K. Fiveash, John B. Wu, Xingen Dobelbower, Michael C. Kim, Robert Y. Jacob, Rojymon ISRN Oncol Clinical Study Purpose. High-risk prostate cancer patients often receive radiotherapy (RT) to pelvic lymphatics (PLs). The aim of this study was to determine the safety margin around clinical target volume for PL (PL-CTV) to construct planning target volume for PL (PL-PTV) and for planning elective PL irradiation. Methods and Materials. Six patients who received RT to PL as part of prostate cancer treatment were identified. To determine average daily shifts of PL, the right and left IVs were contoured at 3 predetermined slices on the daily MV scans and their daily shifts were measured at these 3 levels using a measuring tool. Results. A total of 1,932 observations were made. Daily shifts of IV were random in distribution, and the largest observed shift was 13.6 mm in lateral and 15.4 mm in AP directions. The mean lateral and AP shifts of IV were 2.1 mm (±2.2) and 3.5 mm (±2.7), respectively. The data suggest that AP and lateral margins of 8.9 mm and 6.5 mm are necessary. Conclusions. With daily alignment to the prostate, we recommend an additional PL-CTV to PL-PTV conversion margin of 9 mm (AP) and 7 mm (lateral) to account for daily displacement of PL relative to the prostate. Hindawi Publishing Corporation 2013-03-07 /pmc/articles/PMC3606762/ /pubmed/23533814 http://dx.doi.org/10.1155/2013/941269 Text en Copyright © 2013 Benjamin K. Hinton et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Hinton, Benjamin K.
Fiveash, John B.
Wu, Xingen
Dobelbower, Michael C.
Kim, Robert Y.
Jacob, Rojymon
Optimal Planning Target Volume Margins for Elective Pelvic Lymphatic Radiotherapy in High-Risk Prostate Cancer Patients
title Optimal Planning Target Volume Margins for Elective Pelvic Lymphatic Radiotherapy in High-Risk Prostate Cancer Patients
title_full Optimal Planning Target Volume Margins for Elective Pelvic Lymphatic Radiotherapy in High-Risk Prostate Cancer Patients
title_fullStr Optimal Planning Target Volume Margins for Elective Pelvic Lymphatic Radiotherapy in High-Risk Prostate Cancer Patients
title_full_unstemmed Optimal Planning Target Volume Margins for Elective Pelvic Lymphatic Radiotherapy in High-Risk Prostate Cancer Patients
title_short Optimal Planning Target Volume Margins for Elective Pelvic Lymphatic Radiotherapy in High-Risk Prostate Cancer Patients
title_sort optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606762/
https://www.ncbi.nlm.nih.gov/pubmed/23533814
http://dx.doi.org/10.1155/2013/941269
work_keys_str_mv AT hintonbenjamink optimalplanningtargetvolumemarginsforelectivepelviclymphaticradiotherapyinhighriskprostatecancerpatients
AT fiveashjohnb optimalplanningtargetvolumemarginsforelectivepelviclymphaticradiotherapyinhighriskprostatecancerpatients
AT wuxingen optimalplanningtargetvolumemarginsforelectivepelviclymphaticradiotherapyinhighriskprostatecancerpatients
AT dobelbowermichaelc optimalplanningtargetvolumemarginsforelectivepelviclymphaticradiotherapyinhighriskprostatecancerpatients
AT kimroberty optimalplanningtargetvolumemarginsforelectivepelviclymphaticradiotherapyinhighriskprostatecancerpatients
AT jacobrojymon optimalplanningtargetvolumemarginsforelectivepelviclymphaticradiotherapyinhighriskprostatecancerpatients